Search results
Results from the WOW.Com Content Network
Lobular carcinoma in situ (LCIS) is an incidental microscopic finding with characteristic cellular morphology and multifocal tissue patterns. The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast . [ 1 ]
The morphology axis addresses the microscopic structure of the tumor.. This axis has particular importance because the Systematized Nomenclature of Medicine ("SNOMED") has adopted the ICD-O classification of morphology.
The full chapter can be found on pages 101 to 144 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1. Both volumes can be downloaded for free from the website of the World Health Organization. See here for a tabular overview of primary, secondary, in situ, and benign neoplasms.
For example, the ColoGuard test may be used to screen people over 55 years old for colorectal cancer. [57] Cancer is a longtime-scale disease with various progression steps, molecular diagnostics tools can be used for prognosis of cancer progression. For example, the OncoType Dx test by Genomic Health can estimate risk of breast cancer.
Stage 0 which is in situ disease or Paget's disease of the nipple. Stage 0 is a pre-cancerous or marker condition, either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Stages 1–3 are within the breast or regional lymph nodes. Stage 4 is a metastatic cancer. Metastatic breast cancer has a less favorable prognosis ...
Cells form microtubules in >90% of tumor (smaller than in tubular carcinoma) Pleomorphic Classical-appearing but with pleomorphic cells. It may include signet-ring cells, or plasmacytoid cells (pictured) which have abundant cytoplasm and eccentric nuclei.
Carcinoma in situ (CIS) is a group of abnormal cells. [ 1 ] [ 2 ] While they are a form of neoplasm , [ 3 ] there is disagreement over whether CIS should be classified as cancer . This controversy also depends on the exact CIS in question (e.g., cervical, skin, breast).
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.